

# **Temozolomide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.4	28.09.2024	25454-00026	Date of first issue: 24.10.2014

# **SECTION 1:** Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Temozolomide Formulation
1.2	Relevant identified uses of th	ie s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Pharmaceutical
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD Kilsheelan Clonmel Tipperary, IE
	Telephone	:	353-51-601000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

## **1.4 Emergency telephone number**

+1-908-423-6000

# **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

## Classification (REGULATION (EC) No 1272/2008)

Acute toxicity, Category 2 Eye irritation, Category 2 Germ cell mutagenicity, Category 2 Carcinogenicity, Category 2 Reproductive toxicity, Category 1B

Specific target organ toxicity - repeated exposure, Category 1

H300: Fatal if swallowed.
H319: Causes serious eye irritation.
H341: Suspected of causing genetic defects.
H351: Suspected of causing cancer.
H360FD: May damage fertility. May damage the unborn child.
H372: Causes damage to organs through prolonged or repeated exposure.

#### 2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms



according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Temozolomide Formulation**

Version 5.4	Revision Date: 28.09.2024	SDS Number: 25454-00026	Date of last issue: 06.04.2024 Date of first issue: 24.10.2014
Signa	Il word	: Danger	
Haza	rd statements	H319 Caus H341 Susp H351 Susp H360FD child.	if swallowed. es serious eye irritation. ected of causing genetic defects. ected of causing cancer. May damage fertility. May damage the unborn es damage to organs through prolonged or re- ure.
Preca	autionary statements	P260 Do no	n special instructions before use. of breathe dust. protective gloves/ protective clothing/ eye protec- ection.

Hazardous components which must be listed on the label: Temozolomide

## 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

# **SECTION 3: Composition/information on ingredients**

## 3.2 Mixtures

## Components

h			
Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)



# **Temozolomide Formulation**

Version 5.4	Revision Date: 28.09.2024	SDS Numb 25454-000		ate of last issue: 06.04.2024 ate of first issue: 24.10.2014	
Temo	zolomide	Re	dex-No. egistration nui	mber Acute Tox. 2; H300	>= 50 - < 70
	2010111100			Muta. 2; H341 Carc. 2; H351 Repr. 1B; H360FD STOT RE 1; H372 (Bone marrow, thymus gland, Lymph nodes, spleen)	
(+)-Ta	artaric acid		7-69-4 1-766-0	Eye Dam. 1; H318	>= 1 - < 3

For explanation of abbreviations see section 16.

# **SECTION 4: First aid measures**

# 4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	:	If swallowed, DO NOT induce vomiting. Call a physician or poison control centre immediately. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

## 4.2 Most important symptoms and effects, both acute and delayed



Version 5.4	Revision Date: 28.09.2024		DS Number: 454-00026	Date of last issue: 06.04.2024 Date of first issue: 24.10.2014
Risks		:	Suspected of cau May damage fert	eye irritation. Ising genetic defects.
			Contact with dust the skin.	t can cause mechanical irritation or drying of
	-	meo		d special treatment needed
Treat	ment	:	Treat symptomat	ically and supportively.
SECTION	15: Firefighting meas	sur	es	
5.1 Exting	uishing media			
Suital	ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (0 Dry chemical	
Unsu media	itable extinguishing a	:	None known.	
5.2 Specia	al hazards arising from	the	e substance or mi	xture
Speci fightir	fic hazards during fire-	:	concentrations, a potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a blosion hazard. bustion products may be a hazard to health.
Haza ucts	rdous combustion prod-	:	Carbon oxides Nitrogen oxides ( Metal oxides	NOx)
5.3 Advice	e for firefighters			
	al protective equipment efighters	:		e, wear self-contained breathing apparatus. tective equipment.
Speci ods	fic extinguishing meth-	:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do



# **Temozolomide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.4	28.09.2024	25454-00026	Date of first issue: 24.10.2014

# **SECTION 6: Accidental release measures**

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
<b>6.2 Environmental precautions</b> Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

cannot be contained.

Local authorities should be advised if significant spillages

## 6.3 Methods and material for containment and cleaning up

Methods for cleaning up	<ul> <li>Sweep up or vacuum up spillage and collect in suitable container for disposal.</li> <li>Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).</li> <li>Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.</li> <li>Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.</li> <li>Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.</li> </ul>
-------------------------	--

# 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

# **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Temozolomide Formulation**

Version 5.4	Revision Date: 28.09.2024	SDS Numbe 25454-0002	
Hygie	ene measures	Minimize Keep con Keep aw Take pre Do not e Take car environm If exposu flushing place. W nated clo The effec engineer appropria industria	tainer tightly closed. dust generation and accumulation. tainer closed when not in use. ay from heat and sources of ignition. cautionary measures against static discharges. at, drink or smoke when using this product. to prevent spills, waste and minimize release to the ent. re to chemical is likely during typical use, provide eye ystems and safety showers close to the working hen using do not eat, drink or smoke. Wash contami- thing before re-use. tive operation of a facility should include review of ng controls, proper personal protective equipment, te degowning and decontamination procedures, hygiene monitoring, medical surveillance and the ministrative controls.
7.2 Condi	tions for safe storage,	including an	ncompatibilities
	irements for storage and containers		roperly labelled containers. Store locked up. Keep sed. Store in accordance with the particular national ns.
Advic	e on common storage	Strong o Self-read Organic Flammal Flammal Pyropho Pyropho Self-hea	ic liquids ic solids ing substances and mixtures es and mixtures, which in contact with water, emit e gases
7 3 Snecif	ic end use(s)		
-	fic use(s)	: No data	vailable
		No data	vailable

## 8.1 Control parameters

Occupational Expo	osure Limits
Dust	5 mg/m3
	Value type (Form of exposure): TWA (respirable dust)
	Basis: FOR-2011-12-06-1358

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Temozolomide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.4	28.09.2024	25454-00026	Date of first issue: 24.10.2014

10 mg/m3 Value type (Form of exposure): TWA (total dust) Basis: FOR-2011-12-06-1358

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Temozolomide	85622-93-1	TWA	0.1 ug/m3 (OEB 5)	Internal
		Wipe limit	1 µg/100 cm2	Internal

## Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
(+)-Tartaric acid	Workers	Inhalation	Long-term systemic effects	5,2 mg/m3
	Workers	Skin contact	Long-term systemic effects	2,9 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	1,3 mg/m3
	Consumers	Skin contact	Long-term systemic effects	1,5 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	8,1 mg/kg bw/day
Stearic acid	Workers	Inhalation	Long-term systemic effects	17,63 mg/m3
	Workers	Skin contact	Long-term systemic effects	10 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	4,348 mg/m3
	Consumers	Skin contact	Long-term systemic effects	5 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	2,5 mg/kg bw/day

# Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Environmental Compartment Value		
(+)-Tartaric acid	Fresh water	0,3125 mg/l		
	Freshwater - intermittent	0,514 mg/l		
	Marine water	0,3125 mg/l		
	Sewage treatment plant	10 mg/l		
	Fresh water sediment	1,141 mg/kg dry weight (d.w.)		
	Marine sediment	1,141 mg/kg dry weight (d.w.)		
	Soil	0,0449 mg/kg dry weight (d.w.)		

#### 8.2 Exposure controls

# Engineering measures

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Temozolomide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.4	28.09.2024	25454-00026	Date of first issue: 24.10.2014

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted.

Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipme	ent
Eye/face protection	<ul> <li>Wear safety glasses with side shields or goggles.</li> <li>If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.</li> <li>Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.</li> </ul>
Hand protection	
Material	: Chemical-resistant gloves
Remarks Skin and body protection	<ul> <li>Consider double gloving.</li> <li>Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.</li> </ul>
Respiratory protection Filter type	<ul> <li>If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.</li> <li>Equipment should conform to NS EN 143</li> <li>Particulates type (P)</li> </ul>

## **SECTION 9: Physical and chemical properties**

## 9.1 Information on basic physical and chemical properties

Physical state	:	powder
Colour	:	off-white
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper	:	No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Temozolomide Formulation**

Vers 5.4	sion	Revision Date: 28.09.2024		S Number: 154-00026	Date of last issue: 06.04.2024 Date of first issue: 24.10.2014
	flamma	bility limit			
		explosion limit / Lower bility limit	:	No data available	
	Flash p	point	:	No data available	
	Auto-ig	nition temperature	:	No data available	
	Decom	position temperature	:	No data available	
	pН		:	No data available	
	Viscosi Visc	ty cosity, kinematic	:	No data available	
	Solubili Wat	ity(ies) er solubility	:	No data available	
	Partitio octanol	n coefficient: n- /water	:	No data available	
	Vapour	pressure	:	No data available	•
	Relative	e density	:	No data available	•
	Density	1	:	1 g/cm <sup>3</sup>	
	Relative	e vapour density	:	No data available	
		e characteristics ticle size	:	No data available	
9.2 (	<b>Other ir</b> Explosi	nformation	:	Not explosive	
		ng properties	:	·	mixture is not classified as oxidizing.
		ation rate	:	No data available	
	•	lar weight	:	No data available	

# **SECTION 10: Stability and reactivity**

# 10.1 Reactivity

Not classified as a reactivity hazard.



Version 5.4	Revision Date: 28.09.2024		9S Number: 454-00026	Date of last issue: 06.04.2024 Date of first issue: 24.10.2014
10.2 Cher	nical stability			
Stable	e under normal conditi	ons.		
10.3 Poss	ibility of hazardous r	reaction	ons	
Haza	rdous reactions	:	dling or other	losive dust-air mixture during processing, han- means. h strong oxidizing agents.
10.4 Cond	litions to avoid			
Cond	itions to avoid	:	Heat, flames Avoid dust for	
10.5 Incoi	npatible materials			
Mater	rials to avoid	:	Oxidizing age	ents
No ha	rdous decomposition azardous decompositio	on pro	ducts are know	η.
SECTION	11: Toxicological	infor	mation	
11.1 Infor	mation on hazard cla	isses	as defined in F	Regulation (EC) No 1272/2008
Inforr expos	nation on likely routes sure	of :	Inhalation Skin contact Ingestion Eye contact	
	e toxicity if swallowed.		-	
Prod	uct:			
	e oral toxicity	:	Acute toxicity of Method: Calcu	estimate: 33,93 mg/kg Ilation method
Com	ponents:			
Temo	ozolomide:			
Acute	e oral toxicity	:	LD50 (Dog): 1	9 mg/kg
			LD50 (Rat): 31	15 mg/kg
			LD50 (Mouse)	: 205 mg/kg
(+)-Ta	artaric acid:			
.,	e oral toxicity	:	LD50 (Rat): > Method: OECI	2.000 mg/kg D Test Guideline 423
Acute	e dermal toxicity	:		2.000 mg/kg D Test Guideline 402 Fhe substance or mixture has no acute dermal

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Temozolomide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.4	28.09.2024	25454-00026	Date of first issue: 24.10.2014

# Skin corrosion/irritation

Not classified based on available information.

# Components:

#### (+)-Tartaric acid:

Species	:	Rabbit
Method	:	OECD Test Guideline 404
Result	:	No skin irritation

## Serious eye damage/eye irritation

Causes serious eye irritation.

#### **Components:**

#### (+)-Tartaric acid:

Species Method	-	Bovine cornea OECD Test Guideline 437
Result	:	Irreversible effects on the eye

#### .....

# Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

#### **Components:**

# Temozolomide:

Test Type	: Ma	ximisation Test
Exposure routes	: De	rmal
Species	: Gu	inea pig
Result	: neg	gative

# (+)-Tartaric acid:

Test Type	:	Local lymph node assay (LLNA)
Exposure routes	:	Skin contact
Species	:	Mouse
Method	:	OECD Test Guideline 429
Result	:	negative

# Germ cell mutagenicity

Suspected of causing genetic defects.

#### Components:

## Temozolomide:



Ver 5.4	sion	Revision Date: 28.09.2024		S Number: 454-00026	Date of last issue: 06.04.2024 Date of first issue: 24.10.2014
	Genoto	xicity in vitro	:	Test Type: Bacter Result: positive	ial reverse mutation assay (AMES)
				Test Type: Chrom Test system: Hum Result: positive	osome aberration test in vitro nan lymphocytes
	Germ c sessme	ell mutagenicity- As- ent	:		om in vitro mammalian mutagenicity assays, activity relationship to known germ cell
	(+)-Tar	taric acid:			
		exicity in vitro	:	Result: negative	ial reverse mutation assay (AMES) on data from similar materials
				Result: negative	osome aberration test in vitro
				Test Type: DNA d thesis in mammal Result: positive	amage and repair, unscheduled DNA syn- ian cells (in vitro)
	Genoto	xicity in vivo	:		enicity (in vivo mammalian bone-marrow hromosomal analysis) : Ingestion
		ogenicity sted of causing cancer.			
	Compo	onents:			
	Temoz	olomide:			
	Species		:	Rat	
		ition Route ire time	÷	Oral 6 Months	
	Слрозо		÷	4 mg/kg body wei	ght
	Result Target	Organs	:	positive Mammary gland	
	Carcino ment	ogenicity - Assess-	:	Limited evidence	of carcinogenicity in animal studies
		<b>luctive toxicity</b> Image fertility. May dan	020	e the unborn child	
	-	onents:	lay		
		olomide:			
		on fertility	:	Test Type: Fertility	y/early embryonic development

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Temozolomide Formulation**

Version 5.4	Revision Date: 28.09.2024	SDS Number: 25454-00026	Date of last issue: 06.04.2024 Date of first issue: 24.10.2014
		Species: Rat Application F Fertility: LOA Result: posit	Route: Oral KEL: 8,5 mg/kg body weight
Effects on foetal develop- : ment		Species: Rat Application F Embryo-foet	
Repro sessn	oductive toxicity - As- nent	ity, based on	ce of adverse effects on sexual function and fertil- animal experiments., Clear evidence of adverse evelopment, based on animal experiments.
.,	artaric acid:		
Effect ment	ts on foetal develop-	Species: Rat	Route: Ingestion

## STOT - single exposure

Not classified based on available information.

#### **STOT - repeated exposure**

Causes damage to organs through prolonged or repeated exposure.

#### **Components:**

# Temozolomide:

Exposure routes	: Ingestion
Target Organs	: Bone marrow, thymus gland, Lymph nodes, spleen
Assessment	: Causes damage to organs through prolonged or repeated
	exposure.

## Repeated dose toxicity

#### **Components:**

Temozolom	ide:
<b>o</b> .	

Species NOAEL LOAEL Application Route Exposure time Target Organs	:	Rat, female 4 mg/kg 21 mg/kg Oral 6 Months Lymph nodes, thymus gland, Bone marrow, Reproductive organs
Species NOAEL LOAEL Application Route	:	Rat, male 8,5 mg/kg 34 mg/kg Oral

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version 5.4	Revision Date: 28.09.2024	SDS Number 25454-00026	
	sure time et Organs		des, thymus gland, Bone marrow, male reproductive astrointestinal tract
Expo	EL		
Speci NOAI Applie		: Rat : > 100 mg, : Ingestion : 2 yr	/kg
•	r <b>ation toxicity</b> lassified based on ava	ilable information	
	mation on other haza		l.
Endo	ocrine disrupting prop	oerties	
Produ Asses	<u>uct:</u> ssment	ered to ha REACH A (EU) 2017	ance/mixture does not contain components consid- ave endocrine disrupting properties according to rticle 57(f) or Commission Delegated regulation 7/2100 or Commission Regulation (EU) 2018/605 at 0.1% or higher.
Expe	rience with human ex	posure	
Com	ponents:		
Temo Inges	<b>ozolomide:</b> ition		s: Blood disorders, Nausea, Vomiting, Diarrhoea, Fatigue, hair loss
SECTION	12: Ecological inf	ormation	
12.1 Toxic	city		
	ponents:		
Temo	ozolomide:		
Toxic	ity to fish	Exposure	corhynchus mykiss (rainbow trout)): > 100 mg/l time: 96 h DECD Test Guideline 203
Toxic	ity to daphnia and othe	er : EC50 (Da	phnia magna (Water flea)): > 100 mg/l
		1	4 / 20



Version 5.4	Revision Date: 28.09.2024		0S Number: 454-00026	Date of last issue: 06.04.2024 Date of first issue: 24.10.2014
aqu	atic invertebrates		Exposure time: 4	48 h Test Guideline 202
	Toxicity to algae/aquatic : plants		mg/l Exposure time: 7	rchneriella subcapitata (green algae)): > 90 72 h Test Guideline 201
			mg/l Exposure time: 7	kirchneriella subcapitata (green algae)): 40 72 h Test Guideline 201
Тох	icity to microorganisms	:	Exposure time: Contract Type: Response	3 h
(+)-	Tartaric acid:			
Tox	icity to fish	:	Exposure time: 9	io (zebra fish)): > 100 mg/l 96 h Test Guideline 203
	icity to daphnia and other atic invertebrates	:	Exposure time: 4	magna (Water flea)): 93,313 mg/l 48 h Test Guideline 202
Tox plar	icity to algae/aquatic nts	:	mg/l Exposure time: 7	rchneriella subcapitata (green algae)): 51,40 72 h Test Guideline 201
			mg/l Exposure time: 7	kirchneriella subcapitata (green algae)): 3,12 72 h Test Guideline 201
Тох	icity to microorganisms	:	EC50 : > 1.000 r Exposure time: 3 Method: OECD	
12.2 Per	sistence and degradabil	ity		
<u>Cor</u>	nponents:			
Ten	nozolomide:			
Bior	dogradability		Pocult: rapidly d	ogradablo

Biodegradability	:	Result: rapidly degradable Biodegradation: 83 % Exposure time: 35 d
Stability in water	:	Degradation half life (DT50): < 1 d

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Temozolomide Formulation**

Version 5.4	Revision Date: 28.09.2024		DS Number: 5454-00026	Date of last issue: 06.04.2024 Date of first issue: 24.10.2014
	-Tartaric acid: odegradability	:	Result: Readily b Biodegradation: Exposure time: 2 Method: OECD T	85 %
12.3 Bio	oaccumulative potential			
<u>Co</u>	mponents:			
Pa	mozolomide: rtition coefficient: n- anol/water	:	log Pow: 1,35	
Pa	-Tartaric acid: rtition coefficient: n- anol/water	:	log Pow: -1,91	
	<b>bbility in soil</b> data available			
12.5 Re	sults of PBT and vPvB a	sse	ssment	
	oduct: sessment	:	to be either persi	nixture contains no components considered stent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of
12.6 En	docrine disrupting prope	ertie	es	
	<u>oduct:</u> sessment	:	ered to have end REACH Article 5	ixture does not contain components consid- ocrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.

# 12.7 Other adverse effects

No data available

# **SECTION 13: Disposal considerations**

### 13.1 Waste treatment methods

Product

 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.



Version 5.4	Revision Date: 28.09.2024	SDS Number:Date of last issue: 06.04.202425454-00026Date of first issue: 24.10.2014	
Contaminated packaging		<ul> <li>Empty containers should be taken to an approved waste had dling site for recycling or disposal.</li> <li>If not otherwise specified: Dispose of as unused product.</li> </ul>	an-
SECTION	14: Transport info	mation	
14.1 UN nu	umber or ID number		
ADN		: Not regulated as a dangerous good	
ADR		: Not regulated as a dangerous good	
RID		: Not regulated as a dangerous good	
IMDG		: Not regulated as a dangerous good	
ΙΑΤΑ		: Not regulated as a dangerous good	
14.2 UN pr	oper shipping name		
ADN		: Not regulated as a dangerous good	
ADR		: Not regulated as a dangerous good	
RID		: Not regulated as a dangerous good	
IMDG		: Not regulated as a dangerous good	
ΙΑΤΑ		: Not regulated as a dangerous good	
14.3 Trans	port hazard class(es		
ADN		: Not regulated as a dangerous good	
ADR		: Not regulated as a dangerous good	
RID		: Not regulated as a dangerous good	
IMDG		: Not regulated as a dangerous good	
ΙΑΤΑ		: Not regulated as a dangerous good	
14.4 Packi	ng group		
ADN		: Not regulated as a dangerous good	
ADR		: Not regulated as a dangerous good	
RID		: Not regulated as a dangerous good	
IMDG		: Not regulated as a dangerous good	
ΙΑΤΑ	(Cargo)	: Not regulated as a dangerous good	
ΙΑΤΑ	(Passenger)	: Not regulated as a dangerous good	
	onmental hazards gulated as a dangero	s good	
-	al precautions for us	۶r	
<b>14.7 Mariti</b> Rema	•	according to IMO instruments : Not applicable for product as supplied.	



of

# **Temozolomide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.4	28.09.2024	25454-00026	Date of first issue: 24.10.2014

# **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Not applicable	
REACH - Candidate List of Substances of Very High	:	Not applicable	
Concern for Authorisation (Article 59). REACH - List of substances subject to authorisation	:	Not applicable	
(Annex XIV)			
Regulation (EC) on substances that deplete the ozone layer	:	Not applicable	
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable	
Regulation (EU) No 649/2012 of the European Parlia-	:	Not applicable	
ment and the Council concerning the export and import of dangerous chemicals			
Seveso III: Directive 2012/18/EU of the European Parliam major-accident hazards involving dangerous substances.		and of the Council	on the control
-,		Quantity 1	Quantity 2

		Quantity 1	Quantity 2
H2	ACUTE TOXIC	50 t	200 t

## Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

#### The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

### **SECTION 16: Other information**

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements		
H300	:	Fatal if swallowed.
H318	:	Causes serious eye damage.



# Temozolomide Formulation

Version 5.4	Revision Date: 28.09.2024		9S Number: 454-00026	Date of last issue: 06.04.2024 Date of first issue: 24.10.2014	
H341 H351 H360F H372	D	:	Suspected of cau May damage ferti	lity. May damage the unborn child. to organs through prolonged or repeated	
Full te	xt of other abbreviati	ons			
Acute Tox. Carc. Eye Dam. Muta. Repr. STOT RE FOR-2011-12-06-1358 FOR-2011-12-06-1358 / TWA			Acute toxicity Carcinogenicity Serious eye damage Germ cell mutagenicity Reproductive toxicity Specific target organ toxicity - repeated exposure Norway. Occupational Exposure limits Long term exposure limit		

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - Interna-tional Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods: vPvB - Very Persistent and Very Bioaccumulative

## Further information

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-



# Temozolomide Formulation

Version 5.4	Revision Date: 28.09.2024	SDS Number: 25454-00026	Date of last issue: 06.04.2024 Date of first issue: 24.10.2014
Sheet		cy, http://echa	.europa.eu/
Class	ification of the mixe	ture:	Classification procedure:
Acute	Tox. 2	H300	Calculation method
Eye Ir	rit. 2	H319	Calculation method
Muta.	2	H341	Calculation method
Carc.	2	H351	Calculation method
Repr.	1B	H360FD	Calculation method
STOT RE 1		H372	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN